| Bioactivity | ERD-3111 (Compound 44) is an orally active PROTAC ERα degrader (DC50: 0.5 nM). ERD-3111 inhibits tumor growth in the parental MCF-7 xenograft model with wild-type ER and two clinically relevant ESR1 mutated mice model. ERD-3111 can be used in the research of ER+ breast cancer[1]. |
| Target | ERα |
| Name | ERD-3111 |
| CAS | 2832865-25-3 |
| Formula | C45H46F4N8O5 |
| Molar Mass | 854.89 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen Z, et al. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. J Med Chem. 2023 Aug 30. |
ERD-3111
CAS: 2832865-25-3 F: C45H46F4N8O5 W: 854.89
ERD-3111 (Compound 44) is an orally active PROTAC ERα degrader (DC50: 0.5 nM). ERD-3111 inhibits tumor growth in the pa
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.